Sinopharm Group Co. Ltd.

SEHK:1099 株式レポート

時価総額:HK$63.2b

Sinopharm Group 過去の業績

過去 基準チェック /26

Sinopharm Groupは、平均年間9.4%の収益成長を遂げていますが、 Healthcare業界の収益は、年間 成長しています。収益は、平均年間12.2% 9.8%収益成長率で 成長しています。 Sinopharm Groupの自己資本利益率は11.4%であり、純利益率は1.5%です。

主要情報

9.4%

収益成長率

7.7%

EPS成長率

Healthcare 業界の成長11.3%
収益成長率9.8%
株主資本利益率11.4%
ネット・マージン1.5%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Nov 06
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Oct 04
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Aug 23
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Jul 27
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Jun 16
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

May 13
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Mar 21
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Mar 06
Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Jan 31
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Jan 15
Is Sinopharm Group (HKG:1099) A Risky Investment?

There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Dec 31
There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

Nov 29
Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Nov 14
If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Nov 01
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sep 20
Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sep 05
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Aug 18
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Aug 02
Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Jun 01
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Apr 26
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Feb 27
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Jan 19
Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Is Sinopharm Group (HKG:1099) A Risky Investment?

Nov 18
Is Sinopharm Group (HKG:1099) A Risky Investment?

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Oct 03
Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jul 31
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Jul 10
Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Jun 05
Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Apr 11
We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Mar 21
A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Mar 03
Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jan 09
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Dec 19
Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Dec 01
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sep 23
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Sep 10
A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Aug 28
Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Jun 13
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Jun 06
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

May 24
Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

May 11
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

Mar 20
Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

Mar 05
We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

収支内訳

Sinopharm Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

SEHK:1099 収益、費用、利益 ( )CNY Millions
日付収益収益G+A経費研究開発費
30 Jun 24590,3468,65326,8020
31 Mar 24725,24610,54333,6330
31 Dec 23596,5709,05426,7750
30 Sep 23594,5269,24827,158-210
30 Jun 23591,6268,93626,6570
31 Mar 23553,6848,63525,3460
31 Dec 22552,1488,52625,3460
30 Sep 22546,1477,91424,58484
30 Jun 22533,4037,87024,2760
31 Mar 22528,3837,97023,88419
31 Dec 21521,0517,75923,6560
30 Sep 21507,6117,84723,439126
30 Jun 21501,7707,87423,6520
31 Mar 21474,7986,95622,64342
31 Dec 20456,4157,18721,8730
30 Sep 20442,6746,69821,745-97
30 Jun 20427,3726,17420,4300
31 Mar 20431,9766,55420,442-33
31 Dec 19425,2736,25119,7970
30 Sep 19406,3946,31118,85622
30 Jun 19382,7176,01218,1280
31 Mar 19360,7606,08716,90311
31 Dec 18344,5265,83416,2350
30 Sep 18336,1135,52315,42075
30 Jun 18334,0605,60615,5800
31 Mar 18318,4145,08314,41622
31 Dec 17308,3545,57213,3530
30 Sep 17288,8555,21712,0940
30 Jun 17269,3564,86110,8360
31 Mar 17264,6914,99610,8750
31 Dec 16258,3884,63510,7440
30 Sep 16251,4014,51510,5120
30 Jun 16244,4144,39410,2790
31 Mar 16234,4993,8859,9640
31 Dec 15228,6733,7729,7550
30 Sep 15222,5133,5489,5040
30 Jun 15216,3533,3239,2540
31 Mar 15207,8653,0378,8900
31 Dec 14200,1312,8758,6810
30 Sep 14190,8832,7198,4470
30 Jun 14181,6352,5648,2120
31 Mar 14174,2512,4077,8990
31 Dec 13166,8662,2507,5860

質の高い収益: 1099は 高品質の収益 を持っています。

利益率の向上: 1099の現在の純利益率 (1.5%)は、昨年(1.5%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: 1099の収益は過去 5 年間で年間9.4%増加しました。

成長の加速: 1099は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: 1099は過去 1 年間で収益成長率がマイナス ( -3.2% ) となったため、 Healthcare業界平均 ( -16.9% ) と比較することが困難です。


株主資本利益率

高いROE: 1099の 自己資本利益率 ( 11.4% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘